[1]尚胜君,苏振轩,李雪雁.孟鲁司特钠治疗哮喘慢阻肺重叠综合征患者的疗效及对肺功能的影响[J].内科,2019,14(06):676-678.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2019.06.14]
 SHANG Shengjun,SU Zhenxuan,LI Xueyan.Efficacy of montelukast sodium on asthmatic COPD overlap syndrome and its effect on lung function[J].Internal Medicine of China,2019,14(06):676-678.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2019.06.14]
点击复制

孟鲁司特钠治疗哮喘慢阻肺重叠综合征患者的疗效及对肺功能的影响()
分享到:

《内科》[ISSN:1006-6977/CN:61-1281/TN]

卷:
14卷
期数:
2019年06
页码:
676-678
栏目:
论著
出版日期:
2019-12-30

文章信息/Info

Title:
Efficacy of montelukast sodium on asthmatic COPD overlap syndrome and its effect on lung function
文章编号:
1673-7768(2019)06-0676-03
作者:
尚胜君1苏振轩2李雪雁1
1 许昌市许昌医院呼吸内科,河南省许昌市461000;2 许昌市中医院呼吸内科,河南省许昌市461000
Author(s):
SHANG Shengjun1 SU Zhenxuan2 LI Xueyan1
1 Department of Respiratory, Xuchang Hospital of Xuchang City, Xuchang 461000, Henan Province, China; 2 Department of Respiratory, Xuchang Hospital of Traditional Chinese Medicine, Xuchang 461000, Henan Province, China
关键词:
哮喘慢阻肺重叠综合征孟鲁司特钠肺功能
Keywords:
Asthmatic COPD overlap syndrome Montelukast sodium Lung function
分类号:
R 56
DOI:
DOI:10.16121/j.cnki.cn45-1347/r.2019.06.14
文献标志码:
A
摘要:
目的探讨孟鲁司特钠治疗哮喘慢阻肺重叠综合征患者的临床效果及对患者肺功能的影响。方法选择2016年3月至2019年3月在我院诊治的哮喘慢阻肺重叠综合征患者100例,采用随机数字表法分为两组。对照组患者50例,给予常规治疗;研究组患者50例,在对照组患者治疗的基础上加用孟鲁司特钠治疗。比较两组患者的治疗效果;比较两组患者治疗前、治疗1个月后的第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、第1秒用力呼气容积和用力肺活量比值(FEV1/FVC)、吸气分数[深吸气量(IC)/肺总量(TLC)]。结果治疗1个月后,研究组患者的临床疗效显著优于对照组,治疗总有效率(96.0%)显著高于对照组(84.0%),差异有统计学意义(P<0.05);两组患者的FEV1、FVC、FEV1/FVC、IC/TLC均显著增高,研究组患者的水平显著高于对照组,差异有统计学意义(P<0.05)。结论在常规治疗的基础上,加用孟鲁司特钠治疗哮喘慢阻肺重叠综合征患者临床效果显著,能明显改善患者肺功能,促进患者康复。
Abstract:
ObjectiveTo investigate the clinical effect of montelukast sodium in patients with asthmatic COPD overlap syndrome and its effect on lung function. MethodsA total of 100 patients with asthmatic COPD overlap syndrome diagnosed and treated in our hospital from March 2016 to March 2019 were selected, and were divided into two groups by the random number table method. Fifty patients in control group were administered conventional treatment, based on which another 50 patients in research group were additionally administered montelukast sodium. The efficacy was compared between the two groups; the forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), forced expiratory volume in the first second to forced vital capacity ratio (FEV1/FVC), inspiratory fraction [deep inspiratory capacity (IC)/total lung capacity (TLC)] of patients before treatment and 1 month after treatment were compared between both groups. ResultsAfter 1 month of treatment, the clinical efficacy of the research group was significantly superior to that of the control group. The total effective rate (96.0%) was significantly higher than that of the control group (84.0%), and the differences were statistically significant (P<0.05). FEV1, FVC, FEV1/FVC, and IC/TLC of patients in both groups significantly increased, and the levels of patients in the research group were significantly higher than those in the control group, with the statistically significant differences (P<0.05). ConclusionOn the basis of conventional treatment, additionally employing montelukast on asthmatic COPD overlap syndrome has a prominently clinical effect, which can significantly improve the lung function, and promote a speedy recovery of patients.

相似文献/References:

[1]方海龙 戴珂峰.孟鲁司特钠联合特布他林吸入治疗小儿咳嗽变异性哮喘临床观察[J].内科,2015,(04):484.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2015.04.18]
 [J].Internal Medicine of China,2015,(06):484.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2015.04.18]
[2]傅荧.治疗慢性支气管炎的临床研究[J].内科,2013,(04):368.
 [J].Internal Medicine of China,2013,(06):368.

更新日期/Last Update: 2020-01-03